Feinstein Institute Taps Chad Bouton to Boost Its Leading Bioelectronic Medicine Research Team

Former Battelle Leader Will Oversee
Developing Technologies at New
Center for Bioelectronic Medicine

MANHASSET, NY – Moving its innovative research on bioelectronic medicine a step closer to market, The Feinstein Institute for Medical Research, the research branch of the North Shore-LIJ Health System, announced today the hiring of Chad Bouton as vice president of advanced engineering and the managing director of the Center for Bioelectronic Medicine. Mr. Bouton formerly served as research leader at Battelle Memorial Institute—the world’s largest independent research and development organization—where he spent the last 18 years researching and developing biomedical technology. At the Feinstein Institute, he will continue his groundbreaking research in neurotechnology to treat paralysis and help develop new capabilities and technologies to accelerate the field of bioelectronic medicine.

In the late 1990s, Mr. Bouton developed cancer detection methods that help surgeons pinpoint and remove tumors more rapidly and effectively. Subsequently, he pioneered neural bypass technology that allowed a paralyzed person, for the first time, to regain movement through the use of a brain implant. His recent work at Battelle includes collaboration with the Feinstein Institute on the “Neural Tourniquet,” an initiative that was announced in June and will continue under the leadership of Mr. Bouton and Christopher J. Czura, PhD, vice president of scientific affairs at the Feinstein Institute. Mr. Bouton is the holder of more than 70 patents worldwide and the recipient of numerous awards and distinctions, including special recognition from the U.S. Congress and the National Academy of Engineering.

“We are thrilled to have Chad join our team at this crucial moment in our development,” said Kevin J. Tracey, MD, the Feinstein Institute’s president and CEO. “As we continue to unlock the immense potential of bioelectronic medicine to treat conditions including rheumatoid arthritis, diabetes, paralysis, cancer, and more, we look forward to Chad’s unparalleled expertise. Together we look to create viable technologies that will improve the lives of patients worldwide.”

Bioelectronic medicine is a scientific discipline that brings together molecular medicine, neurophysiology and biomedical engineering, deciphering and manipulating the electrical signal produced by the nervous system to communicate information in order to develop therapies that work by recording, stimulating, and blocking neural signaling. Already proven successful in a number of key clinical trials, this approach promises to deliver therapies superior to pharmaceuticals in terms of efficacy, safety, and cost, without side effects.

“During my eighteen years at Battelle I was very fortunate to have incredible colleagues and work with some of the finest scientific and engineering minds in the world,” Bouton said. “I accepted my new role at the Feinstein Institute because I saw the unique opportunity to build a technology and engineering team to complement its best in class research capability. This winning combination will allow us to accelerate progress in the field of bioelectronic medicine and translate discoveries into cures and treatments for countless patients.”

In addition to Mr. Bouton, the Feinstein Institute will also promote Yousef Al-Abed, PhD, the head of its Center for Molecular Innovation, to division leader of molecular targets. In his previous position, Dr. Al-Abed oversaw the discovery and development of novel therapeutics for human diseases including lupus, arthritis, diabetes, Alzheimer’s disease, and sepsis, as well the successful identification of several new drug candidates. He will work with Mr. Bouton, Dr. Tracey, and others to continue and explore new possibilities for combating disease.

About North Shore-LIJ Health System – North Shore-LIJ is changing its name to Northwell Health in January 2016

One of the nation’s largest health systems, the health system delivers world-class clinical care throughout the New York metropolitan area, pioneering research at The Feinstein Institute for Medical Research, a visionary approach to medical education highlighted by the Hofstra North Shore-LIJ School of Medicine, and healthcare coverage to individuals, families and businesses through the CareConnect Insurance Co. Inc. The health system cares for people at every stage of life at 21 hospitals and about 450 outpatient physician practices throughout the region. The health system’s owned hospitals and long-term care facilities house more than 6,600 beds, employ more than 13,300 nurses and have affiliations with about 10,300 physicians. With a workforce of more than 61,000, the health system is the largest private employer in New York State. For more information, go to northshorelij.com.

About The Feinstein Institute for Medical Research

Headquartered in Manhasset, NY, The Feinstein Institute for Medical Research is home to international scientific leaders in many areas including Parkinson’s disease, Alzheimer’s disease, psychiatric disorders, rheumatoid arthritis, lupus, sepsis, human genetics, pulmonary hypertension, leukemia, neuroimmunology, medicinal chemistry, and bioelectronic medicine. The Feinstein Institute, part of the North Shore-LIJ Health System, ranks in the top 6th percentile of all National Institutes of Health grants awarded to research centers. For more information, visit FeinsteinInstitute.org.

Media Contact:
Emily Ng
(516) 562-2670